The global tissue diagnostics market size is expected to reach USD 8.99 billion by 2030, growing at 7.15% CAGR from 2023 to 2030, according to a new report by Grand View Research, Inc. Accelerating demand for automated tissue diagnostic systems due to a lack of skilled pathologists has driven the tissue diagnostics industry. The advent of advanced imaging techniques, such as autofluorescence, that minimize the need for invasive diagnostics further supplements the market growth.
The use of digital slides has significantly increased in recent years, owing to its associated benefits including flexible magnification and remote access to slides. The growing emphasis on precision medicine is supported by several organizations & companies in the U.S., which is expected to contribute to the market growth. Additionally, companies are supporting the development of precision medicine with novel oncology solutions. For instance, in May 2020, QIAGEN launched new oncology solutions, such as the QCI Interpret One software solution for genomic profiling of tumors. The advancements in imaging techniques are expected to positively influence market growth.
In addition, one of the emerging trends in the tissue diagnostics industry is the integration of digital pathology and artificial intelligence (AI). Digital pathology involves the scanning and digitization of tissue slides, allowing pathologists to review and analyze images remotely. AI algorithms can then be applied to these digital images to aid in the interpretation and analysis of tissue samples. This integration enables faster and more accurate diagnoses, enhances workflow efficiency, and improves patient care. It also facilitates the development of predictive models and precision medicine approaches. As a result, there is a growing demand for digital pathology solutions and AI-driven tissue diagnostics platforms in the market.
With technological improvements in imaging techniques, the sensitivity of detection and diagnosis of breast cancer has also improved. For instance, in May 2023, with an emphasis on AI-guided breast cancer diagnoses, BPGbio recently announced an agreement with the Department of Defense (DoD). The new panel, created with artificial intelligence, is intended to detect women diagnosed with ER+ breast cancer but do not react to hormone therapy, allowing for more suitable treatment alternatives and improving treatment response.
The unique 34-gene breast cancer diagnostic panel from BPGbio will also receive wider evaluation through the Interrogative Biology Platform, focusing on ER+ breast cancers, which are significantly rising. Technological expansion in breast tissue analysis includes procedures for evaluating gene expression, cellular biochemistry, and molecular biology using digital methods, tomosynthesis, CAD, and other methods.
Request a free sample copy or view report summary: Tissue Diagnostics Market Report
The IHC segment held the largest share of the tissue diagnostics industry in 2022. IHC tests are highly adopted as these tests provide precision and help identify the variations between different types of cancer, resulting in the largest revenue share
The digital pathology and workflow segment is expected to grow at the fastest CAGR during the study period. A rise in investments in the development of advanced infrastructure to digitalize images is anticipated to drive the digital pathology segment. Moreover, an increase in the demand for automated modalities owing to a dearth of skilled pathologists further compliments this growth
A large number of breast cancer cases coupled with a rise in the application of digital image processing techniques on histopathological samples for breast cancer detection contributes to the largest share of the tissue diagnostics industry
The hospital segment dominated the tissue diagnostics industry in 2022 due to the high adoption of tissue diagnostics solutions. These solutions provide more accurate results in minimal time than conventional testing procedures
North America accounted for the largest revenue share of the tissue diagnostics industry in 2022 owing to increasing collaborations between pharmaceutical and biotech firms to expand their product offerings
Abbott, QIAGEN, Roche, Siemens, Danaher, Thermo Fisher, and Merck are some key participants operating in the market. Key vendors are engaged in novel product developments, partnerships, and acquisition models to maintain their revenue share in the market
Grand View Research has segmented the global tissue diagnostics market based on technology, application, end-use, and region:
Tissue Diagnostics Technology Outlook (Revenue, USD Million, 2018 - 2030)
Immunohistochemistry
Instruments
Slide Staining Systems
Tissue Microarrays
Tissue Processing Systems
Slide Scanners
Other Products
Consumables
Antibodies
Reagents
Kits
In Situ Hybridization
Instruments
Consumables
Software
Primary & Special Staining
Digital Pathology and Workflow
Whole Slide Imaging
Image Analysis Informatics
Information Management System Storage & Communication
Anatomic Pathology
Instruments
Microtomes & Cryostat Microtomes
Tissue Processors
Automatic Strainers
Other Products
Consumables
Reagents & Antibodies
Probes & Kits
Others
Tissue Diagnostics Application Outlook (Revenue, USD Million, 2018 - 2030)
Breast Cancer
Non-small Cell Lung Cancer
Prostate Cancer
Gastric Cancer
Other Cancers
Tissue Diagnostics End-use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Research Laboratories
Pharmaceutical Organizations
Contract Research Organizations (CROs)
Tissue Diagnostics Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
Spain
France
Italy
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
South Korea
Singapore
Australia
Thailand
Latin America
Brazil
Mexico
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the Tissue Diagnostics Market
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Thermo Fisher Scientific Inc.
Siemens
Danaher
bioMérieux SA
QIAGEN
BD
Merck KGaA
GE Healthcare
BioGenex
Cell Signaling Technology, Inc.
Bio SB
DiaGenic ASA
Agilent Technologies
"The quality of research they have done for us has been excellent..."